Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway.

The Journal of clinical endocrinology and metabolism - 1 Jun 2013

Frasca Francesco, Vella Veronica, Nicolosi Maria Luisa, Messina Rosa Linda, Gianì Fiorenza, Lotta Sonia, Vigneri Paolo, Regalbuto Concetto, Vigneri Riccardo

Abstract excerpt

CONTEXT: Poorly differentiated thyroid carcinomas are refractory to common anticancer therapies, and novel inhibitors are being tested in these deadly malignancies. The epidermal growth factor receptor (EGFR) tyrosine kinase represents an attractive target for treatment because it is up-regulated in thyroid cancer and plays a role in cancer progression. However, EGFR inhibitors have provided poor results in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Survival

Share to ErbB Receptors

Share to EGFR gene

Share to Genes, ras

Share to Mutation

Share to Phosphorylation

Source

Identifiers

PMID: 23559083
DOI: 10.1210/jc.2012-3623

Genes

EGFR
BRAF
RET
HRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway.PMID 23559083Read ↗

Targeting epidermal growth factor receptor 1 signaling in human thyroid-stimulating hormone-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype.Semantic proximity Read ↗

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future PerspectivesSemantic proximity Read ↗

Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma.Semantic proximity Read ↗

Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo.Semantic proximity Read ↗

Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cellsSemantic proximity Read ↗

The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies.Semantic proximity Read ↗

BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.Semantic proximity Read ↗

BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell LinesSemantic proximity Read ↗

Epidermal Growth Factor Receptor 1 Expression Is Upregulated in Undifferentiated Thyroid Carcinomas in HumansSemantic proximity Read ↗

Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.Semantic proximity Read ↗

Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.Semantic proximity Read ↗

Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.